Irlanda - inglés - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - levofloxacin - film-coated tablet - 500 milligram(s) - fluoroquinolones; levofloxacin

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

saja-saudi arabian japanese pharmaceutical co, saudi arabia - levofloxacin - film-coated tablet - 250 mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

jazeera pharmaceutical industries (jpi), saudi arabia - levofloxacin - film-coated tablet - 250 mg

Arabia Saudí - inglés - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

saja-saudi arabian japanese pharmaceutical co, saudi arabia - levofloxacin - film-coated tablet - 250 mg

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levofloxacin hemihydrate - film coated tablet - 250 milligram

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levofloxacin hemihydrate - film coated tablet - 500 milligram

Australia - inglés - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - ivosidenib, quantity: 250 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake; hypromellose acetate succinate; lactose monohydrate - cholangiocarcinoma,tibsovo is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (idh1) r132 mutation after at least one prior line of systemic therapy.,acute myeloid leukaemia,tibsovo is indicated for the treatment of acute myeloid leukaemia (aml) that carries an idh1 r132 mutation:,? as monotherapy, or in combination with azacitidine, in newly diagnosed patients who are not eligible to receive intensive induction chemotherapy; or,? as monotherapy in patients whose aml is relapsed and/or refractory to prior therapy.

Estados Unidos - inglés - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 750 mg - levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin tablets are indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinicalstudies (14.1 ) ]. levofloxacin tablets are indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsie

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - levofloxacin - film-coated tablet - 250 milligram(s) - fluoroquinolones; levofloxacin

Malta - inglés - Medicines Authority

accord healthcare limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - levofloxacin - film-coated tablet - levofloxacin 250 mg - antibacterials for systemic use